ClinicalTrials.gg
RecruitingNCT06318715mDEUpdated Oct 28, 2026

Modified Deep Extubation vs. Standard Awake Extubation

An interventional study of modified deep extubation (mDE) and standard awake extubation in Extubation, sponsored by Samuel Lunenfeld Research Institute, Mount Sinai Hospital. Recruiting at 1 site in Canada. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Samuel Lunenfeld Research Institute, Mount Sinai Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Sex
All
01

Study summary

The proposed study is to compare a modified DE technique, which is regularly used for low-risk patients by staff anesthesiologists at our institution, to a standard awake extubation. This modified deep extubation (mDE) occurs while the patient is still anaesthetized but at a lower dose of anaesthetic gas than previously described, and balanced with long acting opioids to attenuate the airway reaction. As previously stated, the literature shows that the risks of DE are equivalent to those of regular AE practice. Our hypothesis is that mDE will shorten the time from the end of the surgery (completion of last stitch) to the moment the patient is ready to leave the OR by at least 5 minutes when compared to standard AE practice.

Read the detailed description

Study type Randomized Controlled Trial comparing two extubation strategies for low-risk airway elective patients undergoing general anesthesia.

Population

  • Inclusion criteria ASA I-III patients, scheduled for laparoscopic surgery under general anesthesia.
  • Exclusion criteria

    • High-risk patients

      • Documented difficult airway during intubation or developed intraoperatively.
      • Full stomach
      • Pregnant women
      • Emergency surgery
      • BMI>30
      • Intraoperative bleeding leading to transfusion
    • Use of remifentanil during extubation
    • Requirement for prone position for surgical approach (i.e., spine surgery, anal fistulectomy, tumor resection of the back, etc)
    • Absolute indication for awake or deep extubation
    • Use of opioids in chronic pain patients

Procedures Patients that are potential candidates for the study will be selected according to inclusion and exclusion criteria when they undergo assessment on the Pre-Admission Unit (PAU). They will be selected from the PAU assessment list the day before the appointment by the research assistant. For both in person and phone interviews, the PAU personnel (nurse or anesthesiologist) will briefly introduce the patient to the study, and if the patient is interested in participating, the research assistant will approach them with detailed information and a hard-copy leaflet (or an email copy for a phone interview, if the patient agrees) regarding the study.

Informed consent to participate in the study will be taken by the research assistant on the day of surgery during the anesthesia assessment in the preoperative area. Patients will be randomized to either the AE or mDE group. Randomization will be performed in advance, using a computer-generated program and the participant assigned number. The patient and the research assistant will be blinded to the study group allocation. A study investigator, who will know the allocation of the patient, will assign the patient to the anesthesiologists that will provide the anesthesia and perform the extubation process according to group allocation. The anesthesiologists that are part of the research team will perform the extubation in the mDE group, and other attending anesthesiologists will perform their standard awake extubation in the AE group.

In the AE group, the attending anesthesiologist will perform the extubation according to the standard practice as follows:

  1. Sevoflurane (anesthetic gas) will be reduced and the ventilator will be set up to wean patients from mechanical support using the anesthesiologist's method of preference.
  2. Long-acting opioid (morphine or hydromorphone) will be given as per their clinical judgement.
  3. Reversal of neuromuscular block will be performed in all patients and confirmed by a nerve stimulator Train of Four (TOF) ratio of > 0.9, which is the standard practice in patients receiving muscle relaxants as per the last clinical guidelines.
  4. Oral suctioning will be performed.
  5. Patients will be extubated once they are able to obey a verbal command of "open your eyes".
  6. If needed, relief of airway obstruction will be performed at the discretion of the attending anesthesiologist using means such as an oral airway, or a jaw-thrust maneuver.

In the mED group, the attending anaesthesiologist who is familiar with the mDE technique will use the following protocol:

  1. Towards the end of the surgery, sevoflurane will be set at an end-tidal concentration (ET%) of 0.7 MAC, the ventilator will be set to pressure support mode, and the patient will be allowed to breathe spontaneously.
  2. A low dose of long-acting opioid (morphine 0.05 mg/kg or hydromorphone 0.01 mg/kg) will be given before the end of the surgery, according to the anesthesiologist's criteria.
  3. Reversal of neuromuscular block will be performed in all patients and confirmed by a nerve stimulator TOF ratio of > 0.9, which is the standard practice in patients receiving muscle relaxants as per the last clinical guidelines).17
  4. Oral suctioning will be performed while the patient is on Sevoflurane 0.7 MAC. The use of oral airway to avoid airway obstruction will be at the anesthesiologist discretion.
  5. Ventilation support will be changed to the spontaneous mode after confirming an adequate respiratory drive on pressure support mode. Sevoflurane will then be stopped at the time of the last surgical stitch, and the fresh gas flow (FGF) with FiO2 1.0 will be adjusted at 18 litres/minute to optimize gas washout.
  6. The patient will be extubated on spontaneous ventilation as soon as the ET% of sevoflurane drops to 0.4 MAC, once they achieve a minimum tidal volume of more than 3 millilitres per kilogram of ideal body weight and a respiratory rate of 8-12 breaths per minute, while they are still anesthetized under the effect of sevoflurane.
  7. If needed, relief of airway obstruction will be performed at the discretion of the attending anesthesiologist by using means such as an oral airway, or a jaw-thrust maneuver.

During the patient care, the research assistant will record the events and times correlating to the primary and secondary outcomes by direct observation of the extubation process. The patient will also be interviewed by the research assistant in PACU regarding their experience with the recovery process once they are fully awake and ready to be transferred to the ward or discharged home. The patient will be blind to the allocation of the study group until the end of interview. If any problems occur during the extubation process, the patient will be debriefed by the attending anesthesiologist as regularly done in these cases regardless of study participation.

In case the patient was considered as a difficult intubation at the beginning of the case, or that the patient develops respiratory or hemodynamic instability, they would be excluded from the study and the extubation process will be carried out according to the attending anesthesiologist's clinical judgment.

02

Conditions studied

  • Extubation
03

In context

Lead sponsor

Samuel Lunenfeld Research Institute, Mount Sinai Hospital is the lead sponsor of 138 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • laparoscopic surgery under general anesthesia

Exclusion criteria

Exclusion Criteria:

  • High-risk patients:

    • Documented difficult airway during intubation or developed intraoperatively.
    • Full stomach
    • Pregnant women
    • Emergency surgery
    • >30
    • Intraoperative bleeding leading to transfusion
  • Use of remifentanil during extubation
  • Requirement for prone position for surgical approach (i.e., spine surgery, anal fistulectomy, tumor resection of the back, etc)
  • Absolute indication for awake or deep extubation
  • Use of opioids in chronic pain patients
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    modified deep extubation

    This modified deep extubation (mDE) occurs while the patient is still anaesthetized but at a lower dose of anaesthetic gas than previously described, and balanced with long acting opioids to attenuate the airway reaction.

    Procedure: modified deep extubation (mDE)

  • Experimental
    standard awake extubation

    awake extubation (AE) is still considered the standard practice.

    Procedure: standard awake extubation

Interventions

  • Proceduremodified deep extubation (mDE)

    The proposed study is to compare a modified DE technique, which is regularly used for low-risk patients by staff anesthesiologists at our institution, to a standard awake extubation.

  • Procedurestandard awake extubation

    awake extubation (AE) is still considered the standard practice.

06

What researchers measure

Primary outcomes

  1. Time from the end of the surgery to leaving the OR

    Time from the end of the surgery (completion of the last stitch) to the time the patient is ready to safely leave the OR (defined as the moment when the patient breaths spontaneously with SpO2 \> 97 % while receiving oxygen by a facial mask at 6-8 L/min, with normal chest wall movement, no airway obstruction and the presence of ETCO2 waveform).

    Time frame: Time from the end of the surgery (completion of the last stitch) to the time the patient is ready to safely leave the OR

Secondary outcomes

  1. Time from the end of the surgery to extubation

    Time from the end of the surgery (completion of the last stitch) to the moment of extubation (representing the period of extubation that is part of the surgical time).

    Time frame: Time from the end of the surgery (completion of the last stitch) to the moment of extubation

  2. Time from the end of the surgery to discharge from PACU

    Time from the end of the surgery to the moment the patient is ready to be discharged from PACU (Aldrete score greater or equal than 9) as per institutional protocol

    Time frame: Time from the end of the surgery to the moment the patient is ready to be discharged from PACU

  3. oral airway

    Incidence of usage of oral airway.

    Time frame: from intubation to extubation during the surgery/procedure

  4. jaw-thrust maneuver

    Incidence of performance of jaw-thrust maneuver and time of usage.

    Time frame: from intubation to extubation during the surgery/procedure

  5. hypertension

    Incidence of hypertension defined as blood pressure higher than 20% of the baseline during the first 5 minutes after extubation.

    Time frame: During the first 5 minutes after extubation

  6. breath holding

    Incidence of breath holding for more than 30 seconds after extubation.

    Time frame: day 0

  7. bag-mask ventilation

    Incidence of need for bag-mask ventilation after extubation.

    Time frame: day 0

  8. coughing

    Incidence of coughing during the first minute after extubation.

    Time frame: During the first minute after extubation.

  9. bucking

    Incidence of bucking during the first minute after extubation.

    Time frame: During the first minute after extubation.

  10. laryngospasm

    Incidence of laryngospasm (as identified by the attending anesthesiologist).

    Time frame: day 0

  11. treat laryngospasm

    Usage of measures to treat laryngospasm (positive pressure ventilation, 0.5 mg/kg of iv propofol, or 0.3 mg/Kg of succinylcholine, or reintubation).

    Time frame: day 0

  12. desaturation

    Incidence of desaturation (SPO2 less than 92%) after extubation.

    Time frame: day 0

  13. reintubation

    Incidence of reintubation.2

    Time frame: day 0

  14. Patient's experience

    Patient's experience using a questionnaire

    Time frame: day 0

  15. BP

    Systolic and Diastolic Blood Pressure

    Time frame: Just before extubation, and 1 minute and 5 minutes after extubation.

  16. HR

    Hear rate

    Time frame: Just before extubation, and 1 minute and 5 minutes after extubation.

  17. EtCO2

    End-tidal carbon dioxide

    Time frame: Just before extubation, and 1 minute and 5 minutes after extubation.

  18. SaO2

    oxygen saturation level

    Time frame: Just before extubation, and 1 minute and 5 minutes after extubation.

  19. Sevorane MAC

    minimum alveolar concentration (MAC) for sevoflurane

    Time frame: Just before extubation, and 1 minute and 5 minutes after extubation.

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2024 (actual). Primary completion is estimated for Dec 2026, 32 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2024
First posted
Mar 19, 2024
StartActual
Apr 8, 2024
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and oversight details
1 update, last Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Minor edits only
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06318715
Responsible party
Sponsor
First posted
Mar 19, 2024
Start date
Apr 8, 2024
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Oct 28, 2026

Study contacts

naveed siddiqui, MD
Contact
naveed.siddiqui@uhn.ca
416-586-5270

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion